Results 11 to 20 of about 552,864 (311)

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

open access: yes, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R.   +13 more
core   +3 more sources

Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma

open access: yesBMC Cancer, 2023
Glioblastoma multiforme (GBM) is recognized as the prevailing malignant and aggressive primary brain tumor, characterized by an exceedingly unfavorable prognosis.
Lirui Dai   +3 more
doaj   +1 more source

SCP2-mediated cholesterol membrane trafficking promotes the growth of pituitary adenomas via Hedgehog signaling activation

open access: yesJournal of Experimental & Clinical Cancer Research, 2019
Background Metabolic reprogramming is an important characteristic of tumors. In the progression of pituitary adenomas (PA), abnormal glucose metabolism has been confirmed by us before. However, whether cholesterol metabolism is involved in the process of
Xiao Ding   +11 more
doaj   +1 more source

Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis

open access: yesFrontiers in Neurology, 2021
Background: A growing number of evidences suggest that TMZ applications can generate impressive benefits for APT and PC patients. However, the definite role of TMZ for individuals remains unclarified due to the variation between studies.
Mei Luo   +9 more
doaj   +1 more source

Automatic Detection for Acromegaly Using Hand Photographs: A Deep-Learning Approach

open access: yesIEEE Access, 2021
Machine learning assisted diagnosis of acromegaly from facial photographs has been proved feasible in recent years. According to our previous research, facial and limb changes exist in patients with acromegaly at early stage.
Chengbin Duan   +9 more
doaj   +1 more source

Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro [PDF]

open access: yes, 2001
Angiogenesis, the formation of a new blood supply, is an essential step in tumorigenesis. Although vascular endothelial growth factor (VEGF) is known to be a very potent angiogenic factor in most solid tumors, little is known about its production and ...
Gloddek, Jutta   +7 more
core   +1 more source

Generation of isogenic and homozygous MEN1 mutant cell lines from patient-derived iPSCs using CRISPR/Cas9

open access: yesStem Cell Research, 2023
MEN1, an autosomal dominant disorder caused by mutations in the tumor suppressor gene MEN1, manifests with co-occurrence of multiple endocrine/neuroendocrine neoplasms. An iPSC line derived from an index patient carrying the mutation c.1273C>T (p.Arg465*)
Naomi Even-Zohar   +4 more
doaj   +1 more source

Does an Analysis of the Pulsatile Secretion Pattern of Adrenocorticotropin and Cortisol Predict the Result of Transsphenoidal Surgery in Cushing’s Disease. [PDF]

open access: yes, 1993
The endocrinological, surgical, and histological findings of patients with ACTH-dependent Cushing's disease were correlated with the pulsatile secretion pattern of ACTH and cortisol and the outcome after transsphenoidal pituitary surgery.
Brabant, Georg   +5 more
core   +1 more source

Preoperative Fasting C-Peptide Acts as a Promising Predictor of Improved Glucose Tolerance in Patients With Acromegaly After Transsphenoidal Surgery: A Retrospective Study of 64 Cases From a Large Pituitary Center in China

open access: yesFrontiers in Endocrinology, 2019
Purpose: Abnormal glucose metabolism is one of the most frequent acromegaly complications. Improvement of glucose metabolism can be observed only in half of acromegaly patients after surgery.
Zihao Wang   +17 more
doaj   +1 more source

Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review

open access: yesFrontiers in Endocrinology, 2021
Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous evidence supporting available treatment approaches. Recent guidelines emphasize the need to maximize standard therapies as well as the use of temozolomide and ...
Odelia Cooper   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy